40,000 Shares in Prothena Corporation PLC (PRTA) Acquired by Monashee Investment Management LLC

Monashee Investment Management LLC acquired a new stake in shares of Prothena Corporation PLC (NASDAQ:PRTA) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 40,000 shares of the biotechnology company’s stock, valued at approximately $2,232,000. Monashee Investment Management LLC owned 0.11% of Prothena Corporation PLC as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. purchased a new stake in Prothena Corporation PLC during the first quarter valued at approximately $167,000. Stifel Financial Corp purchased a new stake in Prothena Corporation PLC during the first quarter valued at approximately $224,000. Karp Capital Management Corp bought a new stake in shares of Prothena Corporation PLC during the first quarter valued at about $243,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Prothena Corporation PLC during the first quarter valued at about $273,000. Finally, Focused Wealth Management Inc increased its stake in shares of Prothena Corporation PLC by 7.8% in the fourth quarter. Focused Wealth Management Inc now owns 6,250 shares of the biotechnology company’s stock valued at $307,000 after buying an additional 450 shares during the period.

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Prothena Corporation PLC (NASDAQ PRTA) opened at 56.61 on Thursday. The company’s market capitalization is $2.15 billion. Prothena Corporation PLC has a 52 week low of $33.53 and a 52 week high of $68.18. The firm has a 50-day moving average price of $53.15 and a 200-day moving average price of $52.62.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.33. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.26 million. Prothena Corporation PLC had a negative return on equity of 39.67% and a negative net margin of 16,012.49%. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.81) earnings per share. Analysts anticipate that Prothena Corporation PLC will post ($4.76) EPS for the current fiscal year.

WARNING: “40,000 Shares in Prothena Corporation PLC (PRTA) Acquired by Monashee Investment Management LLC” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/06/22/monashee-investment-management-llc-takes-position-in-prothena-co-plc-prta-updated-updated.html.

A number of research analysts have issued reports on PRTA shares. Nomura started coverage on Prothena Corporation PLC in a research note on Wednesday, March 1st. They issued a “buy” rating for the company. Instinet initiated coverage on Prothena Corporation PLC in a research note on Wednesday, March 1st. They issued a “buy” rating and a $87.00 price objective for the company. Oppenheimer Holdings, Inc. set a $70.00 price target on Prothena Corporation PLC and gave the company a “buy” rating in a research report on Thursday, April 6th. Zacks Investment Research raised Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research report on Tuesday, April 18th. Finally, ValuEngine raised Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $75.50.

In related news, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $55.86, for a total value of $195,510.00. Following the sale, the director now directly owns 6,345 shares in the company, valued at $354,431.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $52.25, for a total value of $261,250.00. Following the sale, the insider now directly owns 3,000 shares in the company, valued at $156,750. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by insiders.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply